Daily Left Prefrontal rTMS in the acute treatment of major depression – 2008

rTMS in major depression PDF

Sarah H Lisanby*, Mustafa M Husain, Peter B Rosenquist, Daniel Maixner4, Rosben Gutierrez,  Andrew Krystal6, William Gilmer, Lauren B Marangell, Scott Aaronson, Zafiris J Daskalakis, Randolph Canterbury, Elliott Richelson, Harold A Sackeim and Mark S George

Randomized controlled trials support the antidepressant efficacy of transcranial magnetic stimulation (TMS); however, there is individual variability in the magnitude of response. Examination of response predictors has been hampered by methodological limitations such as small sample sizes and single-site study designs. Data from a multisite sham-controlled trial of the antidepressant efficacy of TMS provided an opportunity to examine predictors of acute outcome. An open-label extension for patients who failed to improve provided the opportunity for confirmatory analysis. Treatment was administered to the left dorsolateral prefrontal cortex at 10 pulses per second, 120% of motor threshold, for a total of 3000 pulses per day. Change on the Montgomery–Asberg Depression Rating Scale after 4 weeks was the primary efficacy outcome. A total of 301 patients with nonpsychotic unipolar major depression at 23 centers were randomized to active or sham TMS. Univariate predictor analyses showed that the degree of prior treatment resistance in the current episode was a predictor of positive treatment outcome in both the controlled study and the open-label extension trial. In the randomized trial, shorter duration of current episode was also associated with a better outcome. In the open-label extension study, absence of anxiety disorder comorbidity was associated with an improved outcome, but duration of current episode was not. The number of prior treatment failures was the strongest predictor for positive response to acute treatment with TMS. Shorter duration of current illness and lack of anxiety comorbidity may also confer an increased likelihood of good antidepressant response to TMS.

 Neuropsychopharmacology (2009) 34, 522 – 534; doi:10.1038/npp.2008.118; published online 13 August 2008

Related Posts

rTMS depression
March 13, 2024
Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)
September 14, 2023
Effect of high frequency versus theta-burst repetitive transcranial magnetic stimulation on suicidality in patients with treatment-resistant depression
September 8, 2023
Effect of repetitive transcranial magnetic stimulation on anxiety symptoms in patients with major depression: An analysis from the THREE‐D trial
September 8, 2023
Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after 2 antidepressant treatment failures
September 8, 2023
rTMS and application for OCD
February 15, 2019
The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy
February 15, 2019
RANZCP Clinical Practice Guidelines for Mood Disorders
February 15, 2019
Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression
February 15, 2019
Repetitive transcranial magnetic stimulation in the treatment of depression
February 15, 2019
TMS Australia. A safety guide for psychiatrists.
May 7, 2018
TMS Social Consensus Review and Treatment for TMS Therapy
May 18, 2016
A multisite, naturalistic, observational study of TMS for patients with pharmacoresistant major depressive disorder – 2014
March 14, 2015
The expanding evidence base for rTMS treatment of depression – 2014
March 6, 2015
TMS for treating depression in elderly patients – 2013
March 6, 2015
Should we expand the toolbox of psychiatric methods to include rTMS? – 2010
March 6, 2015
Efficacy and Safety of TMS in the Acute Treatment of Major Depression – 2007
March 6, 2015
Comparing the Effects of rTMS and ECT in the Treatment of Depression – 2014
March 3, 2015
TMS: Summary of Safety Experience from Acute Exposure – 2008
March 3, 2015
Durability of clinical benefit with TMS – 2010
March 3, 2015